Related to Amylin Allies with JDRF to Evaluate Co-Formulation of Symlin with Insulin

• Diabetes Foundation Allies with Genomics Institute of the Novartis Research Foundation to Accelerate R&D
  
• Amylin to Receive $75M in Obesity Alliance with Takeda
  
• Asterand to Help Amylin Identify Compounds for the Treatment of Inflammatory Diseases
  
• Approval of MannKind’s Inhaled Insulin Further Delayed
  
• Biodel to Obtain $30M from Registered Direct Offering
  
• Amylin Takes Lilly to Court over Diabetes Drug Development Deal with Boehringer Ingelheim
  
• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting
  
• Amylin to Pay Lilly $250M to End Exenatide Partnership and Litigation
  
• JDRF Provides $2.2M Support for KalVista’s Kallikrein Inhibitor DME Drug
  
• Amylin, Lilly Confirm EU Approval of Byetta as Adjunct to Insulin for Type 2 Diabetes
  
• FDA Clears Novo Nordisk’s Levemir for Diabetic Children Aged Two Years and Over
  
• JDRF, Pfizer, Hadassah Medical, and The Hebrew University Forge Type 1 Diabetes Pact
  
• Fast Forward and JDRF Team Up with Axxam for MS and Diabetes Treatments
  
• Sanofi-Aventis Acquires TargeGen and Inks Partnership with JDRF
  
• Amylin and Takeda Halt Phase II Obesity Trial
  
• JDRF to Support Selecta’s Development of Tolerogenic Type 1 Diabetes Vaccine
  
• Amylin and Takeda Shelve Phase II-Stage Combination Obesity Candidate
  
• JDRF, Novo Nordisk Ink Type 1 Diabetes Partnership as Firm Opens Seattle R&D Center
  
• JDRF, BD Expand Diabetes Collaboration to Develop Continuous Glucose Monitoring System
  
• JDRF and Amylin to Back Early Clinical Studies of Metreleptin in Type 1 Diabetes